Surgical failure risk factors

Article

There are several factors that might increase the risk of uncontrolled intraocular pressure (IOP) after phacoviscocanalostomy combination surgery, according to study results published in the September 2008 issue of Journal of Glaucoma.

There are several factors that might increase the risk of uncontrolled intraocular pressure (IOP) after phacoviscocanalostomy combination surgery, according to study results published in the September 2008 issue of Journal of Glaucoma. These factors include preoperative IOP levels, patient age, number of preoperative medications and postoperative IOP spikes.

Masami Park, MD, PhD of the Sensho-kai Eye Institute, Kyoto, Japan and colleagues used multivariate regression analysis to determine the impact of various factors on postoperative IOP in cataract and primary open angle glaucoma (POAG) patients (n=180) with a mean preoperative IOP of 20.2±3.8 mmHg. Five years after surgery, the mean IOP for all patients was 15.3±2.6 mmHg. The surgery was defined as successful if patients achieved an IOP reduction of ≥20%, or an overall IOP of ≤17 mmHg. Without the use of postoperative medications, 31.4% of surgeries were successful; with or without medication, 47.2% were successful.

High preoperative IOP and lower age were found to be negatively correlated to surgical success in the "with or without medications" group; higher preoperative IOP, a greater number of preoperative medications and postoperative IOP spikes (to levels of >30 mmHg) were associated with surgical failure in the "without medications" group; gender and complications (including ruptured Descemet's membrane, hyphaema and fibrin formation) did not have an impact on the surgical success rate of either group.

The team concluded that the risk of failure to control IOP after phacoviscocanalostomy was increased by preoperative IOP levels, lower patient age, a high number of preoperative medications and postoperative IOP spikes.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.